Zacks Investment Research downgraded Fate Therapeutics Inc (NASDAQ:FATE) to Hold in a report released today.
- Updated: October 16, 2016
Zacks Investment Research has downgraded Fate Therapeutics Inc (NASDAQ:FATE) to Hold in a report released on 10/11/2016.
Yesterday Fate Therapeutics Inc (NASDAQ:FATE) traded 0.79% higher at $2.95. The company’s 50-day moving average is $2.87 and its 200-day moving average is $2.17. The last closing price is up 17.75% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 63,000 shares of the stock were exchanged, down from an average trading volume of 273,260
See Chart Below
Fate Therapeutics Inc has a 52 week low of $1.46 and a 52 week high of $5.02 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 4 equity analysts have released a ratings update on the company. The average stock price target is $6.25 with three brokerages rating the company a strong buy, two equity analysts rating the company a buy, 0 brokers rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Fate Therapeutics Inc (NASDAQ:FATE)
Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.